Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)

NCT05024773 is registered in ClinicalTrials.gov with Fidia Farmaceutici s.p.a. as lead sponsor.

NCT NCT05024773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05024773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)
Lead sponsor
Fidia Farmaceutici s.p.a.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 29, 2022
Completion date
December 31, 2030
Enrollment
130 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma in situ (cis)